newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Strategic restructuring extends cash runway to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis Collaboration and license agreement with Everest Medicines to develop and